Publisert 17.07.2017

Regenics wins EU Horizon 2020 Seal of Excellence

Regenics AS, Oslo, Norway, awarded with Horizon 2020 ‘Seal of Excellence’

Our proposal Clinical evaluation of first topical IL-1 beta inhibitor in mild to moderate psoriasis, submitted In May 2017 under Horizon 2020’s SME instrument phase 2, passed all evaluation thresholds, and has been awarded the Horizon 2020 Seal of Excellence.

Regenics AS, Oslo, Norway is developing a CE-marked wound healing device from salmon roe bioactives. We have identified accelerated human ex-vivo 2 degree wound reepitelialization of partially necrotic burn wounds. The bioactive, a heat stabilized component is clinically safe, noniriritative and non-sensitive in pilot human human intact skin safety assessments. Approval for clinical safety testing in humans was approved by the Regional Ethical Committee. The SME Instrument application for 2018-2020 covers a new application for a second indication of mild to moderate psoriasis and to support a clinical proof of principle trial. On March 23 2016, EPO granted novel protection on the production of the heat stable bioactive, where the composition will cover psoriasis use. 8 patents are now granted and 12 patents are pending on the technology.

Psoriasis is an immune-mediated T-cell inflammatory skin disorder. affecting approximately about 225 million people. Severe disease is nowtreated by lymphokine targeted biologics. A need for efficacious topicals for mild to moderate disease has a high medical and societal need.

The project proposal was evaluated by an international panel of independent experts and  was successfully judged with an overall "Excellence criterion" as having a.o. very good to excellent  (highest rating category). The European Commission then delivered the ‘Seal of Excellence’ certificate to Regenics.

Regenics AS: EU Horizon 2020 "Seal of Excellence"

About the Horizon 2020 "Seal of Excellence"


Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.